Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06524375 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period
A Phase 2 study of Chronic Lymphocytic Leukemia, sponsored by Genentech.
- Active
- Registry status
- Phase 2
- Development phase
- 118
- Enrollment target
- 20
- Study locations
NCT06524375 is a Phase 2 study of Chronic Lymphocytic Leukemia that is active but no longer recruiting, run by Genentech. The registered enrollment target is 118 participants, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (35% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT06524375, a Phase 2 study of Chronic Lymphocytic Leukemia, is active but no longer recruiting, sponsored by Genentech.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 118 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of the study is to evaluate if adding venetoclax to participants receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable measurable residual disease \[uMRD \< or 10\^-4 in peripheral blood (PB)\] by end of combination treatment (EOCT) to allow off-treatment period. The acronym BRAVE stands for Btki Responders to Achieve deep remission (or off-treatment periods) with VEnetoclax.
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG cBTKi Monotherapy
Study Locations (20)
Nebraska
- Nebraska Cancer Specialists St Francis - Grand Island - Grand Island
- Nebraska Cancer Specialists - Omaha
Ohio
- Oncology Hematology Care Inc - Cincinnati - USOR - Cincinnati
- Ohio State University - Columbus
Oregon
- Willamette Valley Cancer Institute and Research Center - Eugene
- Asante Rogue Regional Medical Center - Medford
Tennessee
- Tennessee Oncology, PLLC - Chattanooga - Chattanooga
- Tennessee Oncology - Midtown - Nashville
Texas
- MD Anderson Cancer Center - Houston
- Texas Oncology- Northeast Texas - Tyler
Arkansas
- Highlands Oncology Group - Springdale
Colorado
- Rocky Mountain Cancer Centers (Aurora) - USOR - Aurora
Florida
- Cancer Specialists of North Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2024-08-09 |
| Est. Completion | 2030-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06524375
The ClinicalTrials.gov registry entry for NCT06524375 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (35% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.
NCT06524375 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Nebraska, Ohio, Oregon.
Frequently Asked Questions
What is clinical trial NCT06524375 about?
NCT06524375 is a clinical study titled "A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period". The main purpose of the study is to evaluate if adding venetoclax to participants receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable measurable residual disease \[uMRD \< or 10\^-4 in peripheral blood (PB)\] by end of combination treatment (EOCT) to allow off-treatmen...
What is the current status of trial NCT06524375?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 118 participants. The study started on 2024-08-09. Estimated completion is 2030-01-31.
What conditions does trial NCT06524375 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia.
What interventions are being tested in trial NCT06524375?
The interventions under investigation include: Venetoclax (DRUG), cBTKi Monotherapy (DRUG).
Who is sponsoring clinical trial NCT06524375?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06524375 being conducted?
This trial has 20 study locations across Arkansas, Colorado, Florida, Indiana, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 2
-
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RECRUITING · Phase 2
-
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
RECRUITING · Phase 2
-
Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers
RECRUITING · Phase 2
-
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
RECRUITING · Phase 2
-
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.